Structure-Based Optimization of Protein Tyrosine Phosphatase 1B Inhibitors: From the Active Site to the Second Phosphotyrosine Binding Site
Citations Over TimeTop 11% of 2007 papers
Abstract
Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of the insulin and leptin receptor pathways and thus an attractive therapeutic target for diabetes and obesity. Starting with a high micromolar lead compound, structure-based optimization of novel PTP1B inhibitors by extension of the molecule from the enzyme active site into the second phosphotyrosine binding site is described. Medicinal chemistry, guided by X-ray complex structure and molecular modeling, has yielded low nanomolar PTP1B inhibitors in an efficient manner. Compounds from this chemical series were found to be actively transported into hepatocytes. This active uptake into target tissues could be one of the possible avenues to overcome the poor membrane permeability of PTP1B inhibitors.
Related Papers
- → Negative Regulation of a Protein Tyrosine Phosphatase by Tyrosine Phosphorylation(2006)32 cited
- → Synthesis of fluorescent substrates for protein tyrosine phosphatase assays(1998)2 cited
- → Protein Tyrosine Phosphatases as Mediators of Redox Signaling(2009)3 cited
- → The Novel Protein PTPIP51 is Upregulated in Rat Liver under Methotrexate Treatment(2005)
- → BindingDB Entry 50043122: A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.(2014)